As we know, triple-negative breast cancer (TNBC), which is characterized by negativity for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) is a high risk breast cancer that lacks specific targets for treatment selection. This evidence concerns the gene ERBB2 and breast cancer.